Celine Halioua is the founder and CEO of Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs. Her background includes health economics research at Oxford, biotechnology investing, neuroscience research, and work on therapeutics for aging and neurological disease.
Celine Halioua is the founder and CEO of Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs. Her background includes health economics research at Oxford, biotechnology investing, neuroscience research, and work on therapeutics for aging and neurological disease.
Career
Celine Halioua studied at University of Oxford (D.Phil. research in health economics of gene therapy; St Peter’s College), The University of Texas at Austin (Neuroscience and nanobiotechnology), and Uppsala University.
Founder & CEO at Loyal from 2019 to PresentFounded and leads a clinical-stage veterinary medicine company developing drugs intended to extend dogs’ healthspan and lifespan. Oversees development of Loyal’s canine longevity drug programs and regulatory strategy.